Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Prostate

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    May 2024
  1. ZHANG Y, Zhou J
    Responses to queries concerning "Performance of large language models on benign prostatic hyperplasia frequently asked questions".
    Prostate. 2024 May 16. doi: 10.1002/pros.24748.

  2. DAUNGSUPAWONG H, Wiwanitkit V
    Large language models and benign prostatic hyperplasia frequently asked questions.
    Prostate. 2024 May 16. doi: 10.1002/pros.24719.

  3. HUA X, Zhang J, Chen J, Feng R, et al
    Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway.
    Prostate. 2024;84:666-681.
    PubMed     Abstract available

    April 2024
  4. ABID A, Piperdi H, Babar M, Loloi J, et al
    Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review.
    Prostate. 2024 Apr 24. doi: 10.1002/pros.24717.
    PubMed     Abstract available

  5. ROPER C, Slade A, Caras R, Shelton T, et al
    Ejaculatory and erectile function outcomes following holmium laser enucleation of the prostate.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24697.
    PubMed     Abstract available

  6. ZHANG Y, Dong Y, Mei Z, Hou Y, et al
    Performance of large language models on benign prostatic hyperplasia frequently asked questions.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24699.
    PubMed     Abstract available

    March 2024
  7. ZHAO X, Feng R, Chen J, Jiang Q, et al
    4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway.
    Prostate. 2024;84:329-341.
    PubMed     Abstract available

    February 2024
  8. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    PubMed     Abstract available

  9. SHIBAMORI K, Kyoda Y, Shindo T, Hashimoto K, et al
    Maternal diet during gestation affect prostatic tissue component in SHR/Izm offspring.
    Prostate. 2024;84:303-314.
    PubMed     Abstract available

    January 2024
  10. CAVANAUGH D, Urbanucci A, Mohamed NE, Tewari AK, et al
    Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS).
    Prostate. 2024 Jan 9. doi: 10.1002/pros.24656.
    PubMed     Abstract available

  11. WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
    PubMed     Abstract available

  12. JIN R, Forbes CM, Miller NL, Lafin J, et al
    Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24661.
    PubMed     Abstract available

    December 2023
  13. LEE KS, Yoo JW, Kim DH, Jeon S, et al
    A prospective, randomized, open-label, parallel trial comparing the efficacy of alpha-blocker or 5alpha-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyp
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24663.
    PubMed     Abstract available

  14. SCHNEIDER AJ, Serrell EC, Grimes M, Wang S, et al
    Histologic inflammation and collagen content are not positively correlated in human BPH.
    Prostate. 2023;83:1529-1536.
    PubMed     Abstract available

    November 2023
  15. MARIOTTI ACH, Heidrich V, Inoue LT, Coser EM, et al
    Urinary microbiota is associated to clinicopathological features in benign prostatic hyperplasia.
    Prostate. 2023 Nov 13. doi: 10.1002/pros.24649.
    PubMed     Abstract available

    October 2023
  16. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    PubMed     Abstract available

  17. ZHOU H, Xu M, Pan Y, Wang S, et al
    The association between several serum micronutrients and benign prostatic hyperplasia: Results from NHANES 2003-2006.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24641.
    PubMed     Abstract available

  18. HATA J, Matsuoka K, Akaihata H, Meguro S, et al
    The activated complement pathway in the fibrous process of benign prostatic hyperplasia.
    Prostate. 2023 Oct 25. doi: 10.1002/pros.24639.
    PubMed     Abstract available

  19. ZHANG Y, Peng R, Chen Z, Zhang W, et al
    Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study.
    Prostate. 2023;83:1387-1392.
    PubMed     Abstract available

  20. WESTHOFEN T, Bensel M, Schlenker B, Becker A, et al
    The impact of previous inguinal mesh hernioplasty on oncological and patient-reported outcomes following radical prostatectomy.
    Prostate. 2023;83:1313-1322.
    PubMed     Abstract available

    September 2023
  21. FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al
    Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24620.
    PubMed     Abstract available

    July 2023
  22. LV K, Yang G, Wu Y, Xia X, et al
    The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study.
    Prostate. 2023 Jul 16. doi: 10.1002/pros.24598.
    PubMed     Abstract available

    June 2023
  23. SEVIM M, Alkis O, Kartal IG, Kazan HO, et al
    Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain syndrome: A randomized prospective trial.
    Prostate. 2023;83:751-758.
    PubMed     Abstract available

  24. LI Z, Lao Y, Bai Y, Li W, et al
    Re: Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain syndrome: A randomized prospective trial.
    Prostate. 2023;83:896-897.

  25. LEBANI BR, Barcelos ADS, Gouveia DSES, Girotti ME, et al
    The role of transurethral resection of prostate (TURP) in patients with underactive bladder: 12 months follow-up in different grades of detrusor contractility.
    Prostate. 2023;83:857-862.
    PubMed     Abstract available

    May 2023
  26. LEE S, Yoo KH, Kim TS, Cho HJ, et al
    Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US-based insurance claims database.
    Prostate. 2023;83:722-728.
    PubMed     Abstract available

  27. BABAR M, Loloi J, Tang K, Singh S, et al
    Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population.
    Prostate. 2023;83:713-721.
    PubMed     Abstract available

    April 2023
  28. BENGTSEN MB, Heide-Jorgensen U, Borre M, Norgaard M, et al
    Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
    Prostate. 2023 Apr 14. doi: 10.1002/pros.24540.
    PubMed     Abstract available

    March 2023
  29. MIYAZAWA Y, Nakamura T, Takezawa Y, Shimizu N, et al
    A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24514.
    PubMed     Abstract available

    February 2023
  30. BECK J, Rouleau M, Lemire F, Neveu B, et al
    Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Prostate. 2023 Feb 27. doi: 10.1002/pros.24501.
    PubMed     Abstract available

    November 2022
  31. NANDALUR KR, Walker D, Ye H, Al-Katib S, et al
    Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis.
    Prostate. 2022 Nov 7. doi: 10.1002/pros.24457.
    PubMed     Abstract available

  32. NYGARD LH, Talala K, Taari K, Tammela TLJ, et al
    Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Prostate. 2022 Nov 3. doi: 10.1002/pros.24456.
    PubMed     Abstract available

    October 2022
  33. JIN R, Forbes C, Miller NL, Strand D, et al
    Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Prostate. 2022;82:1378-1388.
    PubMed     Abstract available

    September 2022
  34. BENGTSEN MB, Heide-Jorgensen U, Borre M, Knudsen JS, et al
    Acute urinary retention in men: 21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality: A Danish population-based cohort study.
    Prostate. 2022 Sep 20. doi: 10.1002/pros.24440.
    PubMed     Abstract available

  35. SEVIM M, Alkis O, Kartal IG, Coser S, et al
    Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24439.
    PubMed     Abstract available

  36. JIA L, Strand DW, Goueli RS, Gahan JC, et al
    PSA density is associated with BPH cellular composition.
    Prostate. 2022;82:1162-1169.
    PubMed     Abstract available

  37. HUA X, Zhang J, Ge S, Liu H, et al
    CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation.
    Prostate. 2022;82:1223-1236.
    PubMed     Abstract available

    May 2022
  38. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    PubMed     Abstract available

  39. ZHANG M, Jin C, Kong X, Meng J, et al
    Identification of novel susceptibility factors related to CP/CPPS-like symptoms: Evidence from a multicenter case-control study.
    Prostate. 2022;82:772-782.
    PubMed     Abstract available

  40. MOROZOV A, Bazarkin A, Babaevskaya D, Taratkin M, et al
    A systematic review and meta-analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome.
    Prostate. 2022;82:633-656.
    PubMed     Abstract available

    February 2022
  41. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    PubMed     Abstract available

  42. DROGHETTI M, Porreca A, Bianchi L, Piazza P, et al
    Long-term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence.
    Prostate. 2022;82:203-209.
    PubMed     Abstract available

    January 2022
  43. HUANG R, Liu Y, Li B, Wang R, et al
    Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983.
    Prostate. 2022;82:59-77.
    PubMed     Abstract available

  44. KIM SW, Lee J, Oh S, Son H, et al
    Restoration of erectile function by a combination of antiapoptosis by JNK inhibitor and preservation of smooth muscle or endothelium by hepatocyte growth factor in a rat model of cavernous nerve injury.
    Prostate. 2022;82:49-58.
    PubMed     Abstract available

    December 2021
  45. IGARASHI T, Tyagi P, Mizoguchi S, Saito T, et al
    Therapeutic effects of nerve growth factor-targeting therapy on bladder overactivity in rats with prostatic inflammation.
    Prostate. 2021;81:1303-1309.
    PubMed     Abstract available

    November 2021
  46. CHEN J, Zhang LG, Du HX, Zhan CS, et al
    Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1-dependent inhibition of the NLRP3 inflammasome in an EAP mouse model.
    Prostate. 2021;81:1179-1190.
    PubMed     Abstract available

    October 2021
  47. CHEN J, Meng J, Jin C, Mo F, et al
    4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis.
    Prostate. 2021;81:1078-1090.
    PubMed     Abstract available

    September 2021
  48. LIU D, Liu J, Li Y, Liu H, et al
    Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway.
    Prostate. 2021 Sep 23. doi: 10.1002/pros.24241.
    PubMed     Abstract available

  49. CASTRO NFDC, Jubilato FC, Guerra LHA, Santos FCAD, et al
    Therapeutic effects of beta-caryophyllene on proliferative disorders and inflammation of the gerbil prostate.
    Prostate. 2021;81:812-824.
    PubMed     Abstract available

  50. INES M, Babar M, Singh S, Iqbal N, et al
    Real-world evidence with The Rezum System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes.
    Prostate. 2021;81:956-970.
    PubMed     Abstract available

    August 2021
  51. LIAO G, Lee PMY, Zhao S, Ho WM, et al
    Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia: A case-control study in Hong Kong Chinese males.
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24217.
    PubMed     Abstract available

  52. LI Y, Wang Q, Li J, Shi B, et al
    SIRT3 affects mitochondrial metabolic reprogramming via the AMPK-PGC-1alpha axis in the development of benign prostatic hyperplasia.
    Prostate. 2021 Aug 19. doi: 10.1002/pros.24208.
    PubMed     Abstract available

    July 2021
  53. JIN R, Strand DW, Forbes CM, Case T, et al
    The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24190.
    PubMed     Abstract available

  54. BASSILY D, Wong V, Phillips JL, Fraiman M, et al
    Rezum for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24201.
    PubMed     Abstract available

    June 2021
  55. MYKONIATIS I, Pyrgidis N, Kalyvianakis D, Zilotis F, et al
    Comparing two different low-intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two-arm, parallel-group randomized controlled trial.
    Prostate. 2021;81:499-507.
    PubMed     Abstract available

  56. QIAN Q, He W, Liu D, Yin J, et al
    M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin-like growth factor 1 knockdown.
    Prostate. 2021;81:530-542.
    PubMed     Abstract available

    April 2021
  57. QIAN S, Zhang S, Xia W, Xu D, et al
    Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24128.
    PubMed     Abstract available

    March 2021
  58. AYDOGDU O, Gocun PU, Aronsson P, Carlsson T, et al
    Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats.
    Prostate. 2021;81:252-260.
    PubMed     Abstract available

    January 2021
  59. LIU Y, Zhang Y, Zhang M, Meng J, et al
    Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis.
    Prostate. 2021;81:29-40.
    PubMed     Abstract available

    December 2020
  60. ZHANG LG, Yu ZQ, Yang C, Chen J, et al
    Effect of Eriocalyxin B on prostatic inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis.
    Prostate. 2020;80:1394-1404.
    PubMed     Abstract available

  61. MIZOGUCHI S, Mori K, Shin T, Wang Z, et al
    Effects of dutasteride in a rat model of chemically induced prostatic inflammation-Potential role of estrogen receptor beta.
    Prostate. 2020;80:1413-1420.
    PubMed     Abstract available

    November 2020
  62. JAIN S, Samal AG, Das B, Pradhan B, et al
    Escherichia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells.
    Prostate. 2020;80:1341-1352.
    PubMed     Abstract available

  63. GAT Y, Joshua S, Vuk-Pavlovic S, Goren M, et al
    Paying the price for standing tall: Fluid mechanics of prostate pathology.
    Prostate. 2020;80:1297-1303.
    PubMed     Abstract available

    October 2020
  64. WANG K, Pascal LE, Li F, Chen W, et al
    Tight junction protein claudin-1 is downregulated by TGF-beta1 via MEK signaling in benign prostatic epithelial cells.
    Prostate. 2020;80:1203-1215.
    PubMed     Abstract available

  65. CHEN W, Pascal LE, Wang K, Dhir R, et al
    Differential impact of paired patient-derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture.
    Prostate. 2020;80:1177-1187.
    PubMed     Abstract available

    September 2020
  66. EPSTEIN DJ, Thompson LDR, Saleem A, Kao CS, et al
    Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series.
    Prostate. 2020;80:1006-1011.
    PubMed     Abstract available

  67. PENG X, Guo H, Chen J, Wang J, et al
    The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms.
    Prostate. 2020;80:917-925.
    PubMed     Abstract available

  68. SMITH DK, Hasanali SL, Wang J, Kallifatidis G, et al
    Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
    Prostate. 2020;80:938-949.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Andrology is free of charge.